Biopharma & Life Sciences
KalVista Pharmaceuticals Executive Compensation (FY25)
KALV · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Benjamin Palleiko | Latest say-on-pay support = October 1, 2025 |
Free for 3 days · no card
See how KalVista Pharmaceuticals’s pay stands against its peers
- KalVista Pharmaceuticals's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
- Peer-group intelligence, custom peer reruns and governance screens
- Every other company we cover, with alerts when they file
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Velarion Intel, $499/month, or $5,000/year, about two months free: one seat · every company we cover · 7-day refund, with dashboards, peer screens and board-ready briefs.
The KalVista Pharmaceuticals brief, $299
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $449.
Data as of November 12, 2026Latest filing (10-KT/A): April 30, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
159 figures on this page: 152 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
KalVista Pharmaceuticals does not file an annual proxy statement (DEF 14A). Its executive compensation is disclosed directly in its Form 10-K (Part III), which is the filing cited throughout this document. A Form 10-K does not carry a disclosed compensation peer group; those sections are absent from this document for that reason, not from a data gap.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Benjamin Palleiko: $6,772,197 → $5,094,999 (24.8% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is KalVista Pharmaceuticals' chief executive and what were they paid?
Total compensation for Benjamin Palleiko, Chief Executive Officer, came to $5,094,999 in fiscal 2025. Palleiko's total was 24.8% lower than the $6,772,197 reported for fiscal 2024.
What was KalVista Pharmaceuticals' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 89.4% support at the meeting held October 1, 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
T. Andrew Crockett Former Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Benjamin Palleiko President, Chief Business Officer and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Christopher Yea Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
T. Andrew Crockett Former Chief Executive Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | — not reconciled |
Benjamin Palleiko Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Paul Audhya Chief Medical Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Christopher Yea Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Benjamin Palleiko Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Paul Audhya Chief Medical Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Benjamin Palleiko Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Paul Audhya Chief Medical Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Brian Piekos Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Bilal Arif Chief Operating Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Benjamin Palleiko | OPTION | ◇ | — | — | ◇ | — | ◇ | — |
| Bilal Arif | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Benjamin Palleiko | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | August 10, 2035 | |
| Option | ◇ | — | ◇ | May 17, 2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | May 16, 2032 | |
| Bilal Arif | Option | ◇ | — | ◇ | October 5, 2035 |
| Paul Audhya | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | May 16, 2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Bethany Sensenig | ◇ | — | ◇ | — | — | — | ◇ |
Brian J. G. Pereira Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Edward W. Unkart | ◇ | — | ◇ | — | — | — | ◇ |
Nancy Stuart | ◇ | — | ◇ | — | — | — | ◇ |
Patrick Treanor | ◇ | — | ◇ | — | — | — | ◇ |
William Fairey | ◇ | — | ◇ | — | — | — | ◇ |
Laurence Reid | ◇ | — | ◇ | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | October 1, 2025 | = | ◇ | ◇ | ◇ |
| 2024 | October 3, 2024 | = | ◇ | ◇ | ◇ |
| 2023 | October 3, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | September 26, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | October 13, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | September 30, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | October 1, 2020 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Benjamin Palleiko (Chief Executive Officer), FY2025 total compensation $5,094,999 (base salary $688,272) [exec_comp, SEC accession 0001193125-26-197556, filed 2026-04-30]What this page does not include
Everything above is a fact KalVista Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $299Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $299Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
159 figures on this page: 152 cited to the filing that reported them, 7 calculated from figures it prints.
152 cited to the filing
7 calculated from the filing
Documents cited
- 0001193125-26-197556
- 0001193125-25-227478Item 404(a) of Regulation S-K. Additionally, the Board has determined that Ms.
- 0001193125-25-185353Summary Compensation Table
- 0000950170-24-112904
- 0001193125-24-205356
- 0000950170-23-050440Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-22-019610Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-049879Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-20-045741
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “KalVista Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KALV (accessed 2026).
Short form: data: Velarion
The KalVista Pharmaceuticals brief, $299
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $449.
9 filings cited on this page
Method: intel.velarion.ai/methodology
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about KalVista Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}